Rhythm Pharmaceuticals, Inc.
RYTM- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001649904
In the last 90 days, Rhythm Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 6 sales; 305 institutions reported holding it in 13F filings for Q2 2026, worth $8.55B in total; Duquesne Family Office is the only superinvestor holding it.
Q4 2023 vs. Q3 2023
How the institutions holding Rhythm Pharmaceuticals, Inc. changed between Q3 2023 and Q4 2023.
All holders in Q4 2023All holders in Q3 2023
| Measure | Q3 2023 | Q4 2023 | Change |
|---|---|---|---|
| Holders | 144 | 169 | +25 |
| Shares | 68.1M | 66.7M | −1.44M (−2.1%) |
| Value | $1.56B | $3.07B | +$1.50B (+96.3%) |
New holders (45)
Institutions that held Rhythm Pharmaceuticals, Inc. at the end of Q4 2023 but not at the end of Q3 2023.
Sold out (20)
Institutions that held Rhythm Pharmaceuticals, Inc. at the end of Q3 2023 and filed for Q4 2023 without it.
| Institution | Shares, Q3 2023 | Value, Q3 2023 |
|---|---|---|
| Alkeon Capital Management LLC | 1,725,167 | $39.5M |
| Logos Global Management LP | 400,000 | $9.17M |
| Hudson Bay Capital Management LP | 207,500 | $4.76M |
| Cubist Systematic Strategies, LLC | 80,102 | $1.84M |
| First Trust Advisors LP | 75,315 | $1.73M |
| Adage Capital Partners GP, L.L.C. | 43,815 | $1.00M |
| Marshall Wace, LLP | 34,494 | $790.9K |
| Point72 Middle East FZE | 31,181 | $714.8K |
| UBS Oconnor LLC | 30,000 | $687.8K |
| Trexquant Investment LP | 24,514 | $562.0K |
| Fox Run Management, L.L.C. | 17,186 | $394.0K |
| Gsa Capital Partners LLP | 16,465 | $377.0K |
| Engineers Gate Manager LP | 13,071 | $299.7K |
| Man Group plc | – | $256.8K |
| Point72 Asset Management, L.P. | 4,146 | $95.0K |
| Aquatic Capital Management LLC | 3,100 | $71.0K |
| Allspring Global Investments Holdings, LLC | 2,260 | $51.8K |
| Headinvest, LLC | 110 | $2.43K |
| Newbridge Financial Services Group, Inc. | 65 | $1.49K |
| Allworth Financial LP | 5 | $115 |